Key facts
- Notable investors include Cystic Fibrosis Foundation, Deep Science Ventures, Science Entrepreneur Club, Stevenage Bioscience Catalyst.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Panthura
- ·The full record, as it builds
Funding rounds
No funding rounds for Panthura are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Panthura
Developer of next generation of gene therapies intended for cystic fibrosis. The company uses non-viral nano particle delivery systems and therapies will replace mutated DNA with functional DNA to treat diseases, enabling people to get the right treatment.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 5
- Website
- panthura.com/
- Ownership
- Privately Held (backing)
Panthura doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Panthura shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Panthura in its N-PORT filings yet. We sweep new filings monthly.